{
    "Trade/Device Name(s)": [
        "Gold Standard Diagnostics Borrelia burgdorferi IgG/IgM ELISA Test Kit"
    ],
    "Submitter Information": "Gold Standard Diagnostics",
    "510(k) Number": "K203292",
    "Predicate Device Reference 510(k) Number(s)": [
        "K033070",
        "K113847",
        "K113846",
        "K180264"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LSR"
    ],
    "Summary Letter Date": "November 4, 2020",
    "Summary Letter Received Date": "November 9, 2020",
    "Submission Date": "November 4, 2020",
    "Regulation Number(s)": [
        "21 CFR 866.3830"
    ],
    "Regulation Name(s)": [
        "Treponema Pallidum Treponemal Test Reagents"
    ],
    "Analyte Class(es)": [
        "microbiology",
        "immunology"
    ],
    "Analyte(s)": [
        "IgG antibodies to Borrelia burgdorferi",
        "IgM antibodies to Borrelia burgdorferi"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Microplate reader (450 nm)"
    ],
    "Method(s)/Technology(ies)": [
        "ELISA"
    ],
    "Methodologies": [
        "Enzyme immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit",
        "Reagent",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Gold Standard Diagnostics Borrelia burgdorferi IgG/IgM ELISA Test Kit for qualitative detection of IgG and IgM antibodies to B. burgdorferi in human serum as an aid in Lyme disease diagnosis",
    "Indications for Use Summary": "Qualitative test for detection of IgG and IgM antibodies to Borrelia burgdorferi in human serum from symptomatic or suspected patients, for use as first-tier screening or as a second-tier confirmation in standard or modified two-tier Lyme disease testing protocols",
    "fda_folder": "Microbiology"
}